🔎 Trials Near Me

Domov › Rak hipofarinksa › Michigan

Klinične študije za Rak hipofarinksa v Michigan

5 študij za Rak hipofarinksa išče udeležence na lokacijah v Michigan.

Mesta v Michigan

Uradno besedilo študije (angleško)

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • in še 8
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06589804

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • University of Michigan Rogel Cancer Center, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • in še 23
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05136196

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • in še 60
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT02734537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  • McLaren Cancer Institute-Bay City, Bay City
  • McLaren Cancer Institute-Clarkston, Clarkston
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • in še 8
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06532279

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT04198766

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.